dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Pascual, Tomás |
dc.contributor.author | Antunes de Melo Oliveira, Ana Mafalda |
dc.contributor.author | Ciruelos, Eva |
dc.contributor.author | Gavilá Gregori, Joaquín |
dc.contributor.author | Espinosa Bravo, Martin |
dc.contributor.author | Arumí De Dios, Míriam |
dc.contributor.author | Bellet Ezquerra, Meritxell |
dc.contributor.author | Saura Manich, Cristina |
dc.date.accessioned | 2021-12-23T12:54:29Z |
dc.date.available | 2021-12-23T12:54:29Z |
dc.date.issued | 2021-04 |
dc.identifier.citation | Pascual T, Oliveira M, Ciruelos E, Bellet Ezquerra M, Saura C, Gavilá J, et al. SOLTI-1805 TOT-HER3 Study Concept: A Window-of-Opportunity Trial of Patritumab Deruxtecan, a HER3 Directed Antibody Drug Conjugate, in Patients With Early Breast Cancer. Front Oncol. 2021 Apr;11:685. |
dc.identifier.issn | 2234-943X |
dc.identifier.uri | https://hdl.handle.net/11351/6730 |
dc.description | Càncer de mama; Puntuació CelTIL; Patritumab deruxtecan |
dc.description.sponsorship | We thank Daiichi Sankyo for their provision of patritumab deruxtecan and their financial contribution to this clinical study. Pas a Pas and Save the Mama to AP. Fundación SEOM (SEOM 2018 Grant: Fellowship for Training in Research in Reference Centers) to TP. |
dc.language.iso | eng |
dc.publisher | Frontiers Media |
dc.relation.ispartofseries | Frontiers in Oncology;11 |
dc.rights | Attribution 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ |
dc.source | Scientia |
dc.subject | Mama - Càncer - Tractament |
dc.subject | Medicaments - Assaigs clínics |
dc.subject.mesh | Breast Neoplasms |
dc.subject.mesh | /drug therapy |
dc.subject.mesh | Drug Evaluation |
dc.title | SOLTI-1805 TOT-HER3 Study Concept: A Window-of-Opportunity Trial of Patritumab Deruxtecan, a HER3 Directed Antibody Drug Conjugate, in Patients With Early Breast Cancer |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.3389/fonc.2021.638482 |
dc.subject.decs | neoplasias de la mama |
dc.subject.decs | /farmacoterapia |
dc.subject.decs | evaluación de medicamentos |
dc.relation.publishversion | https://doi.org/10.3389/fonc.2021.638482 |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.organismes | Institut Català de la Salut |
dc.contributor.authoraffiliation | [Pascual T] SOLTI Innovative Cancer Research, Barcelona, Spain. Medical Oncology Department, Hospital Clinic de Barcelona, Barcelona, Spain. Translational Genomics and Targeted Therapies in Solid Tumors, August Pi i Sunyer Biomedical Research Institute (Instituto de Investigaciones Biomédicas August Pi i Sunyer), Barcelona, Spain. [Oliveira M, Bellet Ezquerra M, Saura C] SOLTI Innovative Cancer Research, Barcelona, Spain. Servei d’Oncologia Mèdica, Vall d'Hebron Hospital Universitari, Barcelona, Spain. Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain. Breast Cancer Program, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain. Vall d'Hebron Hospital Universitari, Barcelona, Spain. [Ciruelos E] SOLTI Innovative Cancer Research, Barcelona, Spain. Medical Oncology Department, Hospital 12 de Octubre, Madrid, Spain. [Gavilá J] SOLTI Innovative Cancer Research, Barcelona, Spain. Medical Oncology Department, IVO—Fundación Instituto Valenciano de Oncología, Valencia, Spain. [Espinosa-Bravo M] Unitat de Cirurgia de Càncer de Mama, Vall d'Hebron Hospital Universitari, Barcelona, Spain. [Arumi de Dios M] Servei d’Oncologia Mèdica, Vall d'Hebron Hospital Universitari, Barcelona, Spain. Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain |
dc.identifier.pmid | 33968735 |
dc.identifier.wos | 000648033700001 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |